Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos de Lima

Showing results (121-130 of 321) with videos related to

Pageof 33
Sort By:
Molecular Cancer Therapeutics|May 20, 2016
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation ActivitySophia Hu, Masumi Ueda, Lindsay Stetson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2016
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute LeukemiaReinhold Munker, Ruta Brazauskas, Hai Lin Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse RatesMadison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Cancer|February 25, 2003
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima, Farhad Ravandi, Munir Shahjahan, et al.
Transplantation|October 27, 2009
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationStefan O Ciurea, Marcos de Lima, Pedro Cano, et al.
Blood|September 18, 2007
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesMohamed L Sorror, Sergio Giralt, Brenda M Sandmaier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformationStefan O Ciurea, Marcos de Lima, Sergio Giralt, et al.
Bone Marrow Transplantation|May 16, 2019
Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical studyIracema Esteves, Fabio Pires Souza Santos, Juliana Folloni Fernandes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 16, 2007
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing scheduleTimothy Madden, Marcos de Lima, Neil Thapar, et al.
Bone Marrow Transplantation|January 30, 2021
Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteriaNausheen Ahmed, Lucy Li, Patricio Rojas, et al.
Pageof 33

Showing results (121-130 of 321) with videos related to

Sort By:
Pageof 33
Molecular Cancer Therapeutics|May 20, 2016
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation ActivitySophia Hu, Masumi Ueda, Lindsay Stetson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2016
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute LeukemiaReinhold Munker, Ruta Brazauskas, Hai Lin Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse RatesMadison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Cancer|February 25, 2003
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima, Farhad Ravandi, Munir Shahjahan, et al.
Transplantation|October 27, 2009
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationStefan O Ciurea, Marcos de Lima, Pedro Cano, et al.
Blood|September 18, 2007
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesMohamed L Sorror, Sergio Giralt, Brenda M Sandmaier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformationStefan O Ciurea, Marcos de Lima, Sergio Giralt, et al.
Bone Marrow Transplantation|May 16, 2019
Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical studyIracema Esteves, Fabio Pires Souza Santos, Juliana Folloni Fernandes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 16, 2007
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing scheduleTimothy Madden, Marcos de Lima, Neil Thapar, et al.
Bone Marrow Transplantation|January 30, 2021
Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteriaNausheen Ahmed, Lucy Li, Patricio Rojas, et al.
Pageof 33